Scout | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

This opportunity is no longer accepting applications.

grant

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

This grant aims to support research focused on understanding how incretin mimetics (drugs affecting hormones like GLP-1 and GIP-1) influence cancer risk, rather than their short-term effects like weight loss or diabetes. The goal is to attract knowledgeable scientists to explore the mechanisms by which these agents may increase the risk of certain cancers while decreasing the risk of others as…

Source

Agency: National Institutes of Health

Sub-agency: National Cancer Institute

Program: SBIR

Dates

Opportunity Released: August 23, 2023

Open for Submission: August 23, 2023

Submission Deadline: January 7, 2027

Application Window Closes: January 7, 2027

Keywords

Cancer risk

Incretin mimetics

GLP-1

GIP-1

Preclinical studies

Patient-based studies

Obesity-related cancers

Mechanisms of action

Agonists and antagonists

Dual GLP-1/GIP-1 agents

Talented scientists.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers